Andrew Mielach

Andrew W. Mielach has nearly 15 years of life sciences communications experience working with numerous publicly traded and privately held life sciences companies at varying stages of development. As the strategic lead for many of LifeSci’s high-profile clients, Andrew has worked closely with a variety of management teams to establish communications platforms that clearly define each client’s value proposition, and then execute individualized programs that have successfully elevated each company’s profile in the highly influential business, industry, healthcare and mainstream media. Within his areas of expertise include strategic message development, milestone planning, thought leadership, media relations, crisis communications and corporate branding.

Prior to joining LifeSci, Andrew was a managing supervisor for JFK Communications, where he served as an account co-lead helping to drive physician, patient and disease awareness campaigns for multiple clients primarily in the oncology space. Before JFK, Andrew was a vice president with Ruder Finn, Inc., and worked to execute public relations initiatives for Novartis Oncology’s neuroendocrine tumor (NET) franchise and UCB Pharma’s neurology products. Prior to Ruder Finn, Andrew was a vice president at Tiberend Strategic Advisors, Inc., an investor relations and corporate communications firm where he counseled healthcare clients on message development, corporate positioning, content development, milestone planning and media relations.

Andrew received his bachelor’s degree in Communications from Seton Hall University.